Synonyms: ABBV-CLS-7262 | compound 131 [US20220251123A1]
Compound class:
Synthetic organic
Comment: The structure for fosigotifator was obtained from proposed INN list 129 (August 2023) where it is described as a eukaryotic translation initiation factor 2B (eIF2B) activator. Fosigotifator is one of the prodrug compounds claimed in patent US20220251123A1 [2]. It is likely that this is the Abbvie/Calico oral, CNS-penetrant clinical lead ABBV-CLS-7262, that is designed to activate eIF2B and thereby modulate the integrated stress response (ISR) [4] as a mechanism to treat a range of conditions, including neurodegenerative and metabolic diseases [1,3,5].
|
|
References |
1. Hanson FM, Hodgson RE, de Oliveira MIR, Allen KE, Campbell SG. (2022)
Regulation and function of elF2B in neurological and metabolic disorders. Biosci Rep, 42 (6). [PMID:35579296] |
2. Martin KA, Sidrauski C, Dart MJ, Frost JM, Tong Y, Xu X, Shi L, Murauski K, Pliuschev M, Brown BS et al.. (2022)
Prodrug modulators of the integrated stress pathway. Patent number: US20220251123A1. Assignee: AbbVie Inc Calico Life Sciences LLC. Priority date: 02/09/2021. Publication date: 11/08/2022. |
3. Norris K, Hodgson RE, Dornelles T, Allen KE, Abell BM, Ashe MP, Campbell SG. (2021)
Mutational analysis of the alpha subunit of eIF2B provides insights into the role of eIF2B bodies in translational control and VWM disease. J Biol Chem, 296: 100207. [PMID:33334879] |
4. Schoof M, Boone M, Wang L, Lawrence R, Frost A, Walter P. (2021)
eIF2B conformation and assembly state regulate the integrated stress response. Elife, 10. [PMID:33688831] |
5. Slynko I, Nguyen S, Hamilton EMC, Wisse LE, de Esch IJP, de Graaf C, Bruning JB, Proud CG, Abbink TEM, van der Knaap MS. (2021)
Vanishing white matter: Eukaryotic initiation factor 2B model and the impact of missense mutations. Mol Genet Genomic Med, 9 (3): e1593. [PMID:33432707] |